Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
zacks-rank: Archive
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IPSCNegative Net Change MDWDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BigCommerce (BIGC) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BigCommerce (BIGC) delivered earnings and revenue surprises of 100% and 3.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BIGCPositive Net Change AZONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CARMNegative Net Change DRRXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Vital Farms (VITL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Vital Farms (VITL) delivered earnings and revenue surprises of 86.96% and 5.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
VITLPositive Net Change SJMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Benson Hill, Inc. (BHIL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Star Peak Corp II (BHIL) delivered earnings and revenue surprises of -55.56% and 23.98%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BHILNegative Net Change SNAXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Xometry (XMTR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xometry (XMTR) delivered earnings and revenue surprises of 20% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
XMTRPositive Net Change BWENNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
FOLDNegative Net Change MYNZNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Berry Global (BERY) Tops Q2 Earnings Estimates
by Zacks Equity Research
Berry Global (BERY) delivered earnings and revenue surprises of 2.63% and 1.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BERYNegative Net Change GEFPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Plug Power (PLUG) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Plug Power (PLUG) delivered earnings and revenue surprises of -34.38% and 26.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PLUGNegative Net Change PPSIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Shift4 Payments (FOUR) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Shift4 Payments (FOUR) delivered earnings and revenue surprises of -11.48% and 1.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
FOURNegative Net Change DLONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
APYXNegative Net Change MDTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Piedmont Lithium Inc. (PLL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Piedmont Lithium (PLL) delivered earnings and revenue surprises of -12.96% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PLLPositive Net Change ARECPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
LanzaTech Global, Inc. (LNZA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
LanzaTech Global, Inc. (LNZA) delivered earnings and revenue surprises of 0% and 7.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
LNZANegative Net Change GRABPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 13.11% and 4.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
INSMPositive Net Change CUEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AMLXNegative Net Change DERMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Warner Bros. Discovery (WBD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Warner Bros. Discovery (WBD) delivered earnings and revenue surprises of -66.67% and 3.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
WBDNegative Net Change BJNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sterling Check Corp. (STER) Q1 Earnings Lag Estimates
by Zacks Equity Research
Sterling Check (STER) delivered earnings and revenue surprises of -20.83% and 3.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
STERPositive Net Change NUNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
HanesBrands (HBI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HanesBrands (HBI) delivered earnings and revenue surprises of 66.67% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
HBIPositive Net Change UAANo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
XERSNegative Net Change VRCANegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ceva (CEVA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ceva (CEVA) delivered earnings and revenue surprises of -266.67% and 4.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CEVANegative Net Change PXLWNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cogent Communications (CCOI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cogent (CCOI) delivered earnings and revenue surprises of -17.27% and 2.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CCOINegative Net Change SHCOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AKBANegative Net Change XNCRPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of -1.47% and 2.12%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
VTRSNegative Net Change TOIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.08% and 6.79%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
RPRXPositive Net Change ATLCPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MRSNNegative Net Change PRQRPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank